Entrada Therapeutics, Inc. (TRDA) Analyst Estimates Annual - Discounting Cash Flows
TRDA
Entrada Therapeutics, Inc.
TRDA (NASDAQ)
Period Ending: 2029
12-31
2028
12-31
2027
12-31
2026
12-31
2025
12-31
2024
12-31
2023
12-31
2022
12-30
Number of Analysts 2 3 5 5 6 5 2 2
Estimated Revenue
Low 39.9 79.41 15.93 12.37 29.54 184.7 118.5 32.02
Average 80.59 79.41 32.18 24.99 30.45 186.5 239.4 43.43
High 133 79.41 53.1 41.23 31.88 189.2 395 70.31
Estimated EBITDA
Low 25.84 51.44 10.32 8.01 19.13 119.7 76.76 20.74
Average 52.2 51.44 20.84 16.18 19.72 120.8 155.1 28.13
High 86.14 51.44 34.39 26.7 20.65 122.6 255.9 45.54
Estimated EBIT
Low 25.52 50.8 10.19 7.91 18.9 118.2 75.81 20.48
Average 51.55 50.8 20.59 15.98 19.48 119.3 153.1 27.78
High 85.07 50.8 33.97 26.38 20.39 121 252.7 44.98
Estimated Net Income
Low -211.9 -189.1 -188.3 -180.9 -164.2 35.57 41.67 -215.6
Average -114.9 -130.6 -144.5 -160.9 -156.2 40.89 104.4 -82.37
High -39.46 -72.14 -100.6 -140.9 -124.6 46.21 223.8 -78.68
Estimated SGA Expenses
Low 27.39 54.52 10.94 8.49 20.28 126.8 81.37 21.98
Average 55.33 54.52 22.09 17.15 20.91 128.1 164.4 29.82
High 91.3 54.52 36.46 28.31 21.89 129.9 271.2 48.27
Estimated EPS
Low -5.43 -4.85 -4.83 -4.64 -4.21 0.912 1.07 -5.53
Average -2.94 -3.12 -3.99 -4.11 -3.54 1.05 3.11 -3.06
High -1.01 -1.85 -2.58 -3.61 -3.19 1.18 5.74 -2.02
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program